Wockhardt to sell generic version of Abbott's Biaxin tablets

By Elaine Rigoli

Tampa, Fla., June 1 - Wockhardt Ltd. has received approval from the Food and Drug Administration for marketing Clarithromycin tablets in the U.S. market.

Clarithromycin is the generic version of Abbott's Biaxin tablets.

The company's American subsidiary, Wockhardt USA, Inc., is expected to launch the broad-spectrum macrolide antibiotic within the next two weeks, according to a news release.

As per IMS data, the current market for this product in the United States is $113 million.

With Clarithromycin, Wockhardt now has 13 products in the U.S. market, compared to five last year. The company has more than 20 products awaiting FDA approval.

Wockhardt is a technology-driven pharmaceutical and biotechnology company based in Maharashtra, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.